verapamil Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
calcium channel blockers, verapamil derivatives 2815 52-53-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • verapamil
  • RS-Verapamil
  • (+/-)-Verapamil
  • verapamil hydrochloride
  • verapamil HCl
A calcium channel blocker that is a class IV anti-arrhythmia agent.
  • Molecular weight: 454.61
  • Formula: C27H38N2O4
  • CLOGP: 4.47
  • LIPINSKI: 0
  • HAC: 6
  • HDO: 0
  • TPSA: 63.95
  • ALOGS: -5.06
  • ROTB: 13

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.24 g O
0.24 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.75 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 1.50 % Benet LZ, Broccatelli F, Oprea TI
BA (Bioavailability) 22 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 3.70 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 18 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.09 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 2.80 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Aug. 12, 1981 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Completed suicide 3168.29 42.38 698 1898 20336 2335153
Toxicity to various agents 1247.67 42.38 368 2228 32386 2323103
Bradycardia 921.77 42.38 227 2369 9754 2345735
Hypotension 892.30 42.38 285 2311 32151 2323338
Overdose 556.58 42.38 178 2418 19729 2335760
Cardiac arrest 515.36 42.38 157 2439 14773 2340716
Metabolic acidosis 435.16 42.38 113 2483 5885 2349604
Drug hypersensitivity 402.24 42.38 176 2420 46467 2309022
Intentional overdose 389.70 42.38 119 2477 11202 2344287
Drug interaction 383.46 42.38 149 2447 29014 2326475
Cardiogenic shock 377.07 42.38 85 2511 2406 2353083
Death 356.14 42.38 193 2403 81275 2274214
Atrioventricular block complete 353.78 42.38 73 2523 1341 2354148
Suicide attempt 277.81 42.38 92 2504 11190 2344299
Poisoning 217.96 42.38 56 2540 2764 2352725
Nodal rhythm 215.29 42.38 39 2557 343 2355146
Hyperkalaemia 177.15 42.38 56 2540 5837 2349652
Acute respiratory distress syndrome 167.48 42.38 47 2549 3245 2352244
Anuria 164.51 42.38 41 2555 1783 2353706
Hyperglycaemia 161.77 42.38 50 2546 4835 2350654
Acute kidney injury 156.89 42.38 79 2517 28043 2327446
Atrioventricular block 154.24 42.38 36 2560 1181 2354308
Cardio-respiratory arrest 153.01 42.38 56 2540 9090 2346399
Respiratory arrest 146.23 42.38 49 2547 6129 2349360
Dizziness 142.65 42.38 96 2500 58569 2296920
Heart rate decreased 140.38 42.38 42 2554 3634 2351855
Rhabdomyolysis 138.43 42.38 48 2548 6656 2348833
Shock 132.60 42.38 41 2555 3963 2351526
Arrhythmia 127.69 42.38 44 2552 5984 2349505
Somnolence 122.19 42.38 63 2533 23422 2332067
Coma 120.78 42.38 47 2549 9009 2346480
Renal failure 118.38 42.38 56 2540 17293 2338196
Depressed level of consciousness 114.06 42.38 43 2553 7561 2347928
Nodal arrhythmia 111.68 42.38 21 2575 230 2355259
Circulatory collapse 110.23 42.38 35 2561 3685 2351804
Atrial fibrillation 108.10 42.38 49 2547 13719 2341770
Accidental overdose 107.98 42.38 35 2561 3937 2351552
Blood pressure decreased 105.94 42.38 43 2553 9193 2346296
Atrioventricular block first degree 103.71 42.38 25 2571 942 2354547
Loss of consciousness 102.35 42.38 52 2544 18715 2336774
Electrocardiogram QT prolonged 102.21 42.38 40 2556 7774 2347715
Medication error 96.76 42.38 36 2560 6095 2349394
Atrioventricular block second degree 90.90 42.38 21 2575 656 2354833
Pulmonary oedema 86.88 42.38 35 2561 7328 2348161
Nausea 86.52 42.38 95 2501 112094 2243395
Syncope 81.16 42.38 43 2553 16832 2338657
Respiratory failure 81.11 42.38 40 2556 13488 2342001
Electrocardiogram QRS complex prolonged 80.74 42.38 21 2575 1081 2354408
Sinus bradycardia 79.96 42.38 24 2572 2092 2353397
Poisoning deliberate 79.12 42.38 21 2575 1170 2354319
Drug ineffective 78.17 42.38 86 2510 101538 2253951
Dyspnoea 77.34 42.38 76 2520 78657 2276832
Intentional product misuse 75.14 42.38 34 2562 9455 2346034
Vasoplegia syndrome 74.46 42.38 14 2582 153 2355336
Asthenia 73.38 42.38 59 2537 46867 2308622
General physical health deterioration 70.73 42.38 37 2559 14102 2341387
Cardiotoxicity 68.83 42.38 19 2577 1228 2354261
Drug abuse 67.46 42.38 34 2562 11992 2343497
Hyperhidrosis 64.95 42.38 36 2560 15386 2340103
Ventricular extrasystoles 64.47 42.38 20 2576 1946 2353543
Vomiting 60.89 42.38 64 2532 71538 2283951
Pupillary reflex impaired 60.35 42.38 14 2582 445 2355044
Supraventricular tachycardia 59.88 42.38 19 2577 1990 2353499
Hypokalaemia 59.39 42.38 30 2566 10624 2344865
Respiratory depression 58.44 42.38 19 2577 2151 2353338
Lactic acidosis 58.27 42.38 24 2572 5306 2350183
Squamous cell carcinoma of the oral cavity 57.42 42.38 10 2586 68 2355421
Hypoglycaemia 56.81 42.38 27 2569 8380 2347109
Myocardial stunning 55.88 42.38 9 2587 35 2355454
Palpitations 54.85 42.38 33 2563 16423 2339066
Blood creatinine increased 53.90 42.38 28 2568 10505 2344984
Pulseless electrical activity 53.87 42.38 15 2581 1000 2354489
Purpura senile 53.24 42.38 8 2588 17 2355472
Lethargy 52.83 42.38 26 2570 8704 2346785
Presyncope 51.55 42.38 20 2576 3783 2351706
Cardiac failure 50.26 42.38 28 2568 12066 2343423
Pulse absent 50.11 42.38 14 2582 945 2354544
Alanine aminotransferase increased 48.99 42.38 29 2567 14003 2341486
Blood pressure increased 48.83 42.38 31 2565 16955 2338534
Confusional state 47.58 42.38 35 2561 24309 2331180
Haemodialysis 47.25 42.38 16 2580 2053 2353436
Torsade de pointes 45.97 42.38 16 2580 2230 2353259
Headache 45.14 42.38 58 2538 80121 2275368
Pallor 44.83 42.38 18 2578 3724 2351765
Incorrect dose administered 44.57 42.38 24 2572 9671 2345818
Blood pressure systolic decreased 43.96 42.38 12 2584 743 2354746
Haemodynamic instability 42.92 42.38 13 2583 1166 2354323

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Completed suicide 2176.13 50.84 506 1361 15806 1729108
Toxicity to various agents 814.30 50.84 269 1598 28872 1716042
Hypotension 596.64 50.84 215 1652 29439 1715475
Bradycardia 594.40 50.84 168 1699 10366 1734548
Intentional overdose 416.18 50.84 119 1748 7551 1737363
Cardiogenic shock 332.64 50.84 79 1788 2375 1742539
Overdose 325.11 50.84 119 1748 16582 1728332
Shock 314.87 50.84 84 1783 4077 1740837
Suicide attempt 263.10 50.84 83 1784 7298 1737616
Atrioventricular block complete 239.41 50.84 55 1812 1416 1743498
Acute kidney injury 202.13 50.84 106 1761 34838 1710076
Cardiac arrest 173.89 50.84 75 1792 15855 1729059
Death 163.50 50.84 130 1737 87313 1657601
Drug interaction 161.83 50.84 85 1782 27873 1717041
Medication error 158.98 50.84 51 1816 4692 1740222
Coma 148.85 50.84 54 1813 7208 1737706
Atrioventricular block first degree 141.52 50.84 33 1834 903 1744011
Metabolic acidosis 132.80 50.84 46 1821 5356 1739558
Poisoning 130.82 50.84 38 1829 2494 1742420
Hyperkalaemia 112.25 50.84 46 1821 8501 1736413
Sinus bradycardia 108.70 50.84 31 1836 1902 1743012
Nodal rhythm 107.46 50.84 22 1845 320 1744594
Pulmonary oedema 105.78 50.84 41 1826 6545 1738369
Lactic acidosis 100.73 50.84 37 1830 5092 1739822
Poisoning deliberate 92.74 50.84 23 1844 819 1744095
Atrial fibrillation 81.54 50.84 44 1823 15067 1729847
Anuria 78.60 50.84 24 1843 1864 1743050
Acute respiratory distress syndrome 78.60 50.84 28 1839 3523 1741391
Hypoxia 77.88 50.84 32 1835 5931 1738983
Respiratory arrest 75.12 50.84 31 1836 5808 1739106
Atrioventricular block 72.62 50.84 21 1846 1350 1743564
Cardio-respiratory arrest 70.27 50.84 34 1833 9259 1735655
Tachycardia 68.72 50.84 37 1830 12591 1732323
Asthenia 67.08 50.84 53 1814 34617 1710297
Drug abuse 65.93 50.84 37 1830 13652 1731262
Loss of consciousness 60.44 50.84 36 1831 14839 1730075
Syncope 59.41 50.84 35 1832 14134 1730780
Unresponsive to stimuli 54.22 50.84 23 1844 4606 1740308
Heart rate decreased 54.11 50.84 20 1847 2789 1742125
Acidosis 53.76 50.84 17 1850 1480 1743434
Circulatory collapse 53.52 50.84 21 1846 3446 1741468
Hyperthermia 51.72 50.84 17 1850 1674 1743240

Pharmacologic Action:

SourceCodeDescription
ATC C08DA01 CARDIOVASCULAR SYSTEM
CALCIUM CHANNEL BLOCKERS
SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS
Phenylalkylamine derivatives
ATC C08DA51 CARDIOVASCULAR SYSTEM
CALCIUM CHANNEL BLOCKERS
SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS
Phenylalkylamine derivatives
ATC C09BB10 CARDIOVASCULAR SYSTEM
AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
ACE INHIBITORS, COMBINATIONS
ACE inhibitors and calcium channel blockers
FDA MoA N0000000069 Calcium Channel Antagonists
FDA EPC N0000175566 Calcium Channel Blocker
MeSH PA D000889 Anti-Arrhythmia Agents
MeSH PA D002121 Calcium Channel Blockers
MeSH PA D000077264 Calcium-Regulating Hormones and Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D049990 Membrane Transport Modulators
CHEBI has role CHEBI:38070 anti-arrhythmia drug
CHEBI has role CHEBI:35620 vasodilator agent
CHEBI has role CHEBI:35674 antihypertensive agent
MeSH PA D014665 Vasodilator Agents
FDA MoA N0000182141 Cytochrome P450 3A4 Inhibitors
FDA MoA N0000190114 Cytochrome P450 3A Inhibitors
FDA MoA N0000185503 P-Glycoprotein Inhibitors

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Hypertensive disorder indication 38341003 DOID:10763
Atrial fibrillation indication 49436004 DOID:0060224
Paroxysmal supraventricular tachycardia indication 67198005
Prinzmetal angina indication 87343002
Angina pectoris indication 194828000
Acute coronary syndrome indication 394659003
Prevention of Paroxysmal Supraventricular Tachycardia indication
Cardioversion of Atrial Fibrillation indication
Diastolic heart failure off-label use 418304008 DOID:9775
Cluster Headache Prevention off-label use
Hyperkalemia contraindication 14140009
Ventricular tachycardia contraindication 25569003
Complete atrioventricular block contraindication 27885002
Acute cerebrovascular insufficiency contraindication 29322000
Sick sinus syndrome contraindication 36083008 DOID:13884
Immunosuppression contraindication 38013005
Angioedema contraindication 41291007 DOID:1558
Low cardiac output syndrome contraindication 44088000
Low blood pressure contraindication 45007003
Chronic heart failure contraindication 48447003
Bradycardia contraindication 48867003
Lown-Ganong-Levine syndrome contraindication 55475008 DOID:13087
Aortic valve stenosis contraindication 60573004 DOID:1712
Wolff-Parkinson-White pattern contraindication 74390002 DOID:384
Duchenne muscular dystrophy contraindication 76670001 DOID:11723
Transplantation contraindication 77465005
Chronic idiopathic constipation contraindication 82934008
Hereditary angioneurotic edema contraindication 82966003 DOID:14735
Left heart failure contraindication 85232009
Cardiogenic shock contraindication 89138009
Hyponatremia contraindication 89627008
Kidney disease contraindication 90708001 DOID:557
Myasthenia gravis contraindication 91637004 DOID:437
Disorder of connective tissue contraindication 105969002 DOID:65
Liver function tests abnormal contraindication 166603001
Second degree atrioventricular block contraindication 195042002
Hypertrophic cardiomyopathy contraindication 233873004 DOID:11984
Disease of liver contraindication 235856003 DOID:409
Pregnancy, function contraindication 289908002
Renal artery stenosis contraindication 302233006
Neutropenic disorder contraindication 303011007 DOID:1227
Bone marrow depression contraindication 307762000
First Degree Atrioventricular Heart Block contraindication
Neuromuscular Transmission Deficiency contraindication
Hemodialysis with High-Flux Membrane contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.91 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Voltage-dependent L-type calcium channel subunit alpha-1S Ion channel BLOCKER UNKNOWN IUPHAR
Voltage-dependent L-type calcium channel subunit alpha-1C Ion channel BLOCKER IC50 6 WOMBAT-PK CHEMBL
5-hydroxytryptamine receptor 2A GPCR Ki 6.85 PDSP
Alpha-2A adrenergic receptor GPCR Ki 6.66 DRUG MATRIX
Sodium-dependent serotonin transporter Transporter Ki 6.90 DRUG MATRIX
5-hydroxytryptamine receptor 1A GPCR Ki 5.76 DRUG MATRIX
5-hydroxytryptamine receptor 2B GPCR Ki 6.98 DRUG MATRIX
5-hydroxytryptamine receptor 2C GPCR Ki 6.81 DRUG MATRIX
D(3) dopamine receptor GPCR Ki 7.20 DRUG MATRIX
Histamine H2 receptor GPCR Ki 5.59 DRUG MATRIX
Alpha-1D adrenergic receptor GPCR Ki 6.07 DRUG MATRIX
Potassium voltage-gated channel subfamily C member 2 Ion channel EC50 4.90 WOMBAT-PK
Aldehyde oxidase Enzyme IC50 5.46 WOMBAT-PK
Solute carrier family 22 member 2 Transporter IC50 4.07 WOMBAT-PK
Potassium voltage-gated channel subfamily A member 7 Ion channel Kd 4.80 WOMBAT-PK
Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 Ion channel IC50 4.35 WOMBAT-PK
Potassium voltage-gated channel subfamily A member 10 Ion channel BLOCKER IC50 4.30 IUPHAR
Voltage-dependent T-type calcium channel subunit alpha-1H Ion channel BLOCKER Ki 4.49 WOMBAT-PK
Carbonic anhydrase 1 Enzyme WOMBAT-PK
Sodium channel protein type 5 subunit alpha Ion channel WOMBAT-PK
G protein-activated inward rectifier potassium channel 2 Ion channel WOMBAT-PK
Equilibrative nucleoside transporter 4 Transporter INHIBITOR Ki 4.73 IUPHAR
Multidrug resistance protein 1 Transporter Ki 6.52 CHEMBL
Solute carrier family 22 member 1 Transporter IC50 5.17 CHEMBL
Multidrug resistance-associated protein 1 Transporter Ki 4.88 CHEMBL
Potassium voltage-gated channel subfamily H member 2 Ion channel IC50 8 CHEMBL
Sodium channel alpha subunits; brain (Types I, II, III) Ion channel IC50 5.48 CHEMBL
Potassium voltage-gated channel subfamily A member 3 Ion channel IC50 5.10 CHEMBL
ATP-binding cassette sub-family G member 2 Transporter EC50 4.43 CHEMBL
Cytochrome P450 3A4 Enzyme INHIBITOR Ki 6.22 IUPHAR
Two pore calcium channel protein 2 Unclassified BLOCKER IC50 5 IUPHAR
Two pore calcium channel protein 1 Unclassified BLOCKER IC50 4.64 IUPHAR
Alpha-1B adrenergic receptor GPCR Ki 6.03 DRUG MATRIX
Membrane-associated progesterone receptor component 1 Membrane receptor Ki 5.76 DRUG MATRIX
Voltage-dependent L-type calcium channel subunit alpha-1C Ion channel IC50 6 CHEMBL
Voltage-dependent L-type calcium channel subunit alpha-1S Ion channel Ki 7.24 CHEMBL
Translocator protein Membrane receptor IC50 8.85 CHEMBL
Chloroquine resistance transporter Unclassified IC50 4.52 CHEMBL
Voltage-gated L-type calcium channel Ion channel IC50 8.43 CHEMBL
Voltage-dependent L-type calcium channel subunit alpha-1C Ion channel IC50 7.41 CHEMBL
Muscarinic acetylcholine receptor M2 GPCR EC50 4.51 CHEMBL
5-hydroxytryptamine receptor 1A GPCR IC50 5.52 CHEMBL
Alpha-1A adrenergic receptor GPCR IC50 5.68 CHEMBL
Potassium voltage-gated channel subfamily C member 2 Unclassified BLOCKER EC50 4.90 IUPHAR

External reference:

IDSource
4019969 VUID
N0000148054 NUI
C0042523 UMLSCUI
D00619 KEGG_DRUG
47898004 SNOMEDCT_US
4019969 VANDF
11170 RXNORM
372754009 SNOMEDCT_US
d00048 MMSL
004515 NDDF
CJ0O37KU29 UNII
2122 INN_ID
CHEMBL6966 ChEMBL_ID
CHEMBL1280 ChEMBL_ID
DB00661 DRUGBANK_ID
152-11-4 SECONDARY_CAS_RN
CHEBI:9948 CHEBI
D014700 MESH_DESCRIPTOR_UI
2520 PUBCHEM_CID
2406 IUPHAR_LIGAND_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
CALAN HUMAN PRESCRIPTION DRUG LABEL 1 0025-1851 TABLET, FILM COATED 80 mg ORAL NDA 13 sections
CALAN HUMAN PRESCRIPTION DRUG LABEL 1 0025-1861 TABLET, FILM COATED 120 mg ORAL NDA 13 sections
CALAN SR HUMAN PRESCRIPTION DRUG LABEL 1 0025-1891 TABLET, FILM COATED, EXTENDED RELEASE 240 mg ORAL NDA 12 sections
CALAN SR HUMAN PRESCRIPTION DRUG LABEL 1 0025-1901 TABLET, FILM COATED, EXTENDED RELEASE 120 mg ORAL NDA 12 sections
CALAN SR HUMAN PRESCRIPTION DRUG LABEL 1 0025-1911 TABLET, FILM COATED, EXTENDED RELEASE 180 mg ORAL NDA 12 sections
Tarka HUMAN PRESCRIPTION DRUG LABEL 2 0074-3287 TABLET, FILM COATED, EXTENDED RELEASE 180 mg ORAL NDA 13 sections
Tarka HUMAN PRESCRIPTION DRUG LABEL 2 0074-3288 TABLET, FILM COATED, EXTENDED RELEASE 240 mg ORAL NDA 13 sections
Tarka HUMAN PRESCRIPTION DRUG LABEL 2 0074-3289 TABLET, FILM COATED, EXTENDED RELEASE 240 mg ORAL NDA 13 sections
Tarka HUMAN PRESCRIPTION DRUG LABEL 2 0074-3290 TABLET, FILM COATED, EXTENDED RELEASE 240 mg ORAL NDA 13 sections
Verapamil Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-0512 TABLET, FILM COATED 80 mg ORAL ANDA 11 sections
Verapamil Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-0772 TABLET, FILM COATED 120 mg ORAL ANDA 11 sections
Verapamil Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-1411 TABLET, FILM COATED, EXTENDED RELEASE 240 mg ORAL ANDA 11 sections
Verapamil Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-2120 TABLET, FILM COATED, EXTENDED RELEASE 120 mg ORAL ANDA 11 sections
Verapamil Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-2180 TABLET, FILM COATED, EXTENDED RELEASE 180 mg ORAL ANDA 11 sections
Verapamil Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-6320 CAPSULE, EXTENDED RELEASE 120 mg ORAL ANDA 11 sections
Verapamil Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-6380 CAPSULE, EXTENDED RELEASE 180 mg ORAL ANDA 11 sections
Verapamil Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-6440 CAPSULE, EXTENDED RELEASE 240 mg ORAL ANDA 11 sections
Verapamil Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0409-1144 INJECTION, SOLUTION 2.50 mg INTRAVENOUS ANDA 12 sections
Verapamil Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0409-4011 INJECTION, SOLUTION 2.50 mg INTRAVENOUS ANDA 12 sections
Verapamil Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0409-9633 INJECTION, SOLUTION 2.50 mg INTRAVENOUS ANDA 12 sections
Verapamil Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0591-0343 TABLET, FILM COATED 80 mg ORAL ANDA 12 sections
Verapamil Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0591-0345 TABLET, FILM COATED 120 mg ORAL ANDA 12 sections
Verapamil Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0591-0404 TABLET, FILM COATED 40 mg ORAL ANDA 12 sections
Verapamil Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0591-2880 CAPSULE, DELAYED RELEASE PELLETS 120 mg ORAL NDA 12 sections
Verapamil Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0591-2882 CAPSULE, DELAYED RELEASE PELLETS 180 mg ORAL NDA 12 sections
Verapamil Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0591-2884 CAPSULE, DELAYED RELEASE PELLETS 240 mg ORAL NDA 12 sections
Verapamil Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0591-2886 CAPSULE, DELAYED RELEASE PELLETS 360 mg ORAL NDA 12 sections
Verapamil Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0615-3588 TABLET, FILM COATED, EXTENDED RELEASE 180 mg ORAL ANDA 11 sections
Verapamil Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0615-3589 TABLET, FILM COATED, EXTENDED RELEASE 240 mg ORAL ANDA 11 sections
Verapamil Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0615-7618 TABLET, FILM COATED 80 mg ORAL ANDA 13 sections